Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05925621 · ClinicalTrials.gov registry record
Cognitive Neurology Unit Clinical Registry
A clinical trial of Alzheimer Disease, sponsored by Beth Israel Deaconess Medical Center.
- Recruiting
- Registry status
- 500
- Enrollment target
- 1
- Study location
NCT05925621 is a study of Alzheimer Disease that is actively recruiting participants, run by Beth Israel Deaconess Medical Center. The registered enrollment target is 500 participants, below the 2,749-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (82% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05925621, a study of Alzheimer Disease, is actively recruiting participants, sponsored by Beth Israel Deaconess Medical Center.
- RECRUITING
- Registry status
- 500 participants
- Enrollment target
- 1
- Study location
Study Summary
A Prospective Comparative Study Of Monoclonal Antibodies For The Treatment Of Alzheimer's Disease
Conditions Studied
Interventions
- DRUG Lecanemab
Study Locations (1)
Massachusetts
- Beth Israel Deaconess Medical Center - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 500 participants |
| Start Date | 2023-07-16 |
| Est. Completion | 2028-06 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05925621
The ClinicalTrials.gov registry entry for NCT05925621 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 500 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,749-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (82% lower). The listed sponsor is Beth Israel Deaconess Medical Center, which has 488 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Alzheimer Disease appearing as the primary indexed condition, and to 1 intervention - of which Lecanemab is the first listed.
NCT05925621 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT05925621 about?
NCT05925621 is a clinical study titled "Cognitive Neurology Unit Clinical Registry". A Prospective Comparative Study Of Monoclonal Antibodies For The Treatment Of Alzheimer's Disease
What is the current status of trial NCT05925621?
This trial is currently recruiting. The enrollment target is 500 participants. The study started on 2023-07-16. Estimated completion is 2028-06.
What conditions does trial NCT05925621 study?
This clinical trial studies the following conditions: Alzheimer Disease.
What interventions are being tested in trial NCT05925621?
The interventions under investigation include: Lecanemab (DRUG).
Who is sponsoring clinical trial NCT05925621?
This trial is sponsored by Beth Israel Deaconess Medical Center, which has 488 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05925621 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alzheimer Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-2)
RECRUITING · Phase 3
-
Sex-Specific Effects of Endocrine Disruption on Aging and Alzheimer's Disease
RECRUITING · Phase 4
-
Systemic and Central Inflammation in AD
RECRUITING · Phase 2
-
I-CARE 2: Mobile Telehealth to Reduce Alzheimer'S-related Symptoms
RECRUITING · NA
-
Autologous Activated Adipose-derived Stem Cells (RB-ADSC) Injected Directly Into the Brain for Mild to Moderate Alzheimer's Disease
RECRUITING · Phase 1
-
Psilocybin for Depression in People With Mild Cognitive Impairment or Early Alzheimer's Disease
RECRUITING · Early Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.